Angie DeMichele

Abstract 1401: A novel statistical framework for surrogate endpoint prediction of survival in neoadjuvant breast cancer trials.

Keli S. Santos-Parker, Jessica R Santos-Parker, W. Fraser Symmans, Laura J. Esserman et autres

us, fr, gb, nl, es, se (code pays fourni par la source)

Abstract 2994: Integrative pathway analysis of I-SPY2 HER2+ breast cancers reveals drug-repurposing opportunities

Kingsley Chow, T. B. V. Bui, Denise M. Wolf, Annuska M. Glas et autres

us (code pays fourni par la source)

5MO Pretreatment circulating tumor (ct)DNA predicts metastatic recurrence in patients (pts) with high-risk early breast cancer (eBC) enrolled in the I-SPY 2 trial

MJM Magbanua, DM Wolf, Rosalyn W. Sayaman, Lamorna Brown Swigart et autres

us (code pays fourni par la source)

Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer Rapid Recommendation Update

Brittany Harvey, Angie DeMichele

Abstract PD10-07: Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies

Hatem Soliman, Denise M. Wolf, Jo Chien, Christina Yau et autres

us (code pays fourni par la source)

Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL

Denise M. Wolf, Christina Yau, Michael J. Campbell, Hatem Soliman et autres

us (code pays fourni par la source)

Predictors of efficacy in patients (pts) with hormone receptor–positive/ human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3

H. S. Rugo, Massimo Cristofanilli, Sibylle Loibl, Nadia Harbeck et autres

us, de, jp, kr, gb (code pays fourni par la source)

Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL

Michael J. Campbell, Christina Yau, Jennifer Bolen, Scott Vandenberg et autres

us (code pays fourni par la source)

Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL

Michael J. Campbell, Christina Yau, Jennifer Bolen, Scott R. VandenBerg et autres

us (code pays fourni par la source)

I-SPY2

Laura J. Esserman, Nola M. Hylton, Smita Asare, Christina Yau et autres

Effect of raloxifene on endometrial cancer risk in a population-based, case-control study

Angie DeMichele, Andrea B. Troxel, Arthur Weber, J. Berlin et autres

Telomerase vaccination of metastatic breast cancer patients induces antigen-specific tumor infiltrating lymphocytes and tumor necrosis

Susan M. Domchek, Kevin R. Fox, A. Recio, Lynn M. Schuchter et autres

us (code pays fourni par la source)